Autistic spectrum disorder (ASD) is known as a disease of wide prevalence in children.
DSM-IV is currently used as the diagnosis of ASD in clinical psychiatry. However, it is
diffi cult to provide a defi nitive diagnosis of ASD. As the reason, characteristics of ASD are very
similar to that of schizophrenia or social anxiety disorder. Th erefore, if children develop ASD
until in early childhood and cannot be received treatment, they will have a high risk secondary
disorder, depression etc. As a result, development of simple clinical laboratory test for ASD is
necessary for early detection and rapid cure of that disorder. Recently, it has been suggested that
ASD patients have low level of OXT in their plasma. Th erefore, OXT might be able to be used as
one of the biomarker for ASD, psychiatric disorder.
In this report, we developed highly sensitive bioluminescent enzyme immunoassay (BLEIA)
for OXT utilizing the Luciferin/luciferase detection system.
On this assay, the detection limit was 1 pg/assay (B0-3SD). Additionally, in the result of
the cross reactivity examination, we conclude that BLEIA was developed high sensitively and
specifi cally measurement for OXT. But it might not be able to measure of OXT in plasma of
ASD patients, which is estimated to very low level. Finally, we will propose to the modifi cation
of secondary antibody immobilized magnetic particles preparation, assay protocol and labeled
antigen or re-selection of anti-OXT antibody, to contribute as clinical laboratory test for
psychiatric disorder, ASD
Yoshihiro Sano has completed his Ph.D at the age of 28 years from Showa University. His work is development
of high sensitive analytical method for peptide hormone etc, now.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals